KC Business Journal's Year in Review: Biggest biotech breakthroughs
CHAMP app lets parents monitor single-ventricle patients' condition with a tablet
Several Kansas City researchers made strides in 2016, ranging from taking their first product to market to making a key discovery toward a new cure. From among the area's plethora of pharmaceutical companies, startups, academic research and new technologies, Kansas City continued to grow its reputation for life sciences offerings.
Children's Mercy expands cardiac monitoring app
Children's Mercy received recognition for its CHAMP (Cardiac High Acuity Monitoring Program). In the two years since it was deployed, the program has dramatically reduced infant mortality between heart surgeries for babies born with a single ventricle.
Dr. Girish Shirali collaborated with the hospital's IT team in 2014 to develop the platform, which lets parents monitor their child's condition with a tablet and share information digitally with physicians. Most babies with single-ventricle heart disease face a 20 percent mortality rate between their first and second surgery, but since launching the program two years ago, Children's Mercy has seen zero deaths. With these outcomes, the program received several grants to expand the tech to other children's hospitals across the U.S.
Learn more about CHAMP.
Read more about this year's biotech breakthroughs from the KC Business Journal.